BioMarin Uses Itamar Medical's Endo-PAT2000 In Successful Phase 2 Study For New Treatment For Sickle Cell Disease

 04.12.2008 12:09   medicalnewstoday.com

Itamar Medical, an international medical technology company developing noninvasive diagnostic technology using the Peripheral Arterial Tone (PAT™) Signal, announced today the use of the company's patented Endo-PAT2000 in BioMarin Pharmaceutical Inc.'s phase 2 study of patients with Sickle Cell Disease (SCD). The Endo-PAT2000 was used to measure endothelial function in a study designed to evaluate whether the drug 6R-BH4 can improve endothelial function in SCD patients.

World Medical Equipment